Arrowhead Pharmaceuticals Inc - Asset Resilience Ratio

Latest as of September 2025: 59.96%

Arrowhead Pharmaceuticals Inc (ARWR) has an Asset Resilience Ratio of 59.96% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. See Arrowhead Pharmaceuticals Inc (ARWR) working capital ratio to evaluate short-term liquidity relative to the company's equity base.

Liquid Assets

$830.66 Million

Cash + Short-term Investments

Total Assets

$1.39 Billion

All company assets

Resilience Assessment

Very High

Financial Resilience Level

Asset Resilience Ratio Trend (2004–2025)

This chart shows how Arrowhead Pharmaceuticals Inc's Asset Resilience Ratio has changed over time. For the complete balance sheet picture, see Arrowhead Pharmaceuticals Inc total assets.

Liquid Assets Composition Over Time

This chart breaks down Arrowhead Pharmaceuticals Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. Explore investment intensity of Arrowhead Pharmaceuticals Inc to see how much of total assets are deployed in long-term investments.

Current Liquid Assets Breakdown

Component	Amount	% of Total Assets
Cash & Equivalents	$0.00	0%
Short-term Investments	$830.66 Million	59.96%
Total Liquid Assets	$830.66 Million	59.96%

Asset Resilience Insights

Very High Liquidity: Arrowhead Pharmaceuticals Inc maintains exceptional liquid asset reserves at 59.96% of total assets.
This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
The company has significant short-term investments, indicating active treasury management.

Arrowhead Pharmaceuticals Inc Industry Peers by Asset Resilience Ratio

Compare Arrowhead Pharmaceuticals Inc's asset resilience ratio with other companies in the same industry.

Company	Industry	Asset Resilience Ratio
argenx NV ADR NASDAQ:ARGX	Biotechnology	15.95%
Madrigal Pharmaceuticals Inc NASDAQ:MDGL	Biotechnology	62.31%
Shanghai RAAS Blood Products Co Ltd Class A SHE:002252	Biotechnology	2.03%
Halozyme Therapeutics Inc NASDAQ:HALO	Biotechnology	12.71%
Tubize-Fin BR:TUB	Biotechnology	2.50%
Aurinia Pharmaceuticals Inc NASDAQ:AUPH	Biotechnology	33.23%
Nanobiotix NASDAQ:NBTX	Biotechnology	4.71%
Innovita Biological Technology Co. Ltd. A SHG:688253	Biotechnology	65.12%

Annual Asset Resilience Ratio for Arrowhead Pharmaceuticals Inc (2004–2025)

The table below shows the annual Asset Resilience Ratio data for Arrowhead Pharmaceuticals Inc.

Year	Asset Resilience Ratio (%)	Liquid Assets	Total Assets	Change
2025-09-30	47.77%	$692.82 Million	$1.45 Billion	-2.97pp
2024-09-30	50.73%	$578.28 Million	$1.14 Billion	+12.50pp
2023-09-30	38.24%	$292.74 Million	$765.55 Million	-0.55pp
2022-09-30	38.79%	$268.39 Million	$691.94 Million	+12.97pp
2021-09-30	25.82%	$183.35 Million	$710.15 Million	-7.08pp
2020-09-30	32.90%	$171.91 Million	$522.50 Million	+22.35pp
2019-09-30	10.55%	$36.90 Million	$349.85 Million	-31.03pp
2018-09-30	41.57%	$46.40 Million	$111.61 Million	+2.38pp
2017-09-30	39.19%	$40.77 Million	$104.02 Million	--
2016-09-30	0.00%	$0.00	$128.18 Million	--
2015-09-30	13.26%	$17.54 Million	$132.27 Million	+1.42pp
2014-09-30	11.84%	$21.65 Million	$182.82 Million	-12.35pp
2013-09-30	24.19%	$9.03 Million	$37.33 Million	+23.55pp
2012-09-30	0.64%	$106.50K	$16.53 Million	-3.35pp
2011-09-30	3.99%	$634.59K	$15.89 Million	+3.73pp
2005-09-30	0.26%	$76.88K	$29.04 Million	-3.83pp
2004-09-30	4.09%	$487.89K	$11.92 Million	--

pp = percentage points

About Arrowhead Pharmaceuticals Inc

NASDAQ:ARWR USA Biotechnology

Market Cap

$9.85 Billion

Market Cap Rank

#2369 Global

#872 in USA

Share Price

$70.67

Change (1 day)

-12.40%

52-Week Range

$29.13 - $89.59

All Time High

$90.47